|
| |
DendreonDendreon Corporation (Nasdaq: DNDN) is a Seattle-based biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. Through innovative science and technology, we are striving to develop and commercialize products that address unmet medical need, improve survival and have a favorable safety profile. Our active immunotherapy, monoclonal antibody and small molecule development capabilities provide us with a solid foundation on which to build a variety of oncology treatments that meet these objectives.
| Contact Details: |
| 3005 First Avenue |
| Seattle |
| Washington |
| 98121 |
| United States of America |
| Tel: | (206) 256-4545 |
| Fax: | (206) 256-0571 |
| Email: | clinicalshared@dendreon.com |
| WWW: | www.dendreon.com/
|
|
Loading...
|
Recent Publications by Dendreon: |  |
CD54 is a surrogate marker of antigen presenting cell activation.
There is no single universally accepted hallmark of antigen presenting... | 21st August, 2008
| Dendreon Corporation, 3005 1st Avenue, Seattle, WA 98121, USA.
| Cancer Immunol Immunother. 2008 Sep;57(9):1381-90. Epub 2008 Feb 23.
DOI Direct Link |
Smart adjuvants.
Although vaccine adjuvants have been used for almost a century, alum is... | 19th October, 2007
| Scientist II, Dendreon Corporation, 3005 1st Avenue, Seattle, WA 98121,
| Expert Rev Vaccines. 2007 Jun;6(3):391-400.
DOI Direct Link |
Tumor immunotherapy with alternative reading frame peptide antigens.
The translation machinery of a eukaryotic cell produces errors in decoding... | 16th March, 2005
| Dendreon Corporation, 3005 1st Avenue, Seattle, WA 98121, USA.
| Immunobiology. 2004;209(7):535-44.
|
Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function.
CD4(+)CD25+ T regulatory (Treg) cells have been shown to critically... | 16th February, 2005
| Department of Pediatrics, University of Minnesota Cancer Center, Division
| Blood. 2005 Jan 15;105(2):750-8. Epub 2004 Sep 16.
DOI Direct Link |
High cell density induces spontaneous bifurcations of dissolved oxygen controllers during CHO cell fermentations.
High cell density cultures of CHO cells growing in a bioreactor under... | 20th May, 2004
| Abgenix Inc, 6701 Kaiser Drive, Fremont, California 94555, USA.
| Biotechnol Bioeng. 2003 Oct 20;84(2):224-32.
DOI Direct Link |
→View more Dendreon research publications. |
Press Releases on Dendreon:
|
 |
| Dendreon Receives FDA Acknowledgement of Complete Response |
20th November, 2009 |
Dendreon Corporation |
SEATTLE, Nov. 20 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's
|
| Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization |
11th November, 2009 |
Dendreon Corporation |
-- Elected Ian Clark and Pedro Granadillo to Board of Directors. Beginning
Jan. 1, Mr. Clark will be chief executive officer and head of North
American commercial operations at
|
| Dendreon Completes Submission of Biologics License Application for PROVENGE |
2nd November, 2009 |
Dendreon Corporation |
SEATTLE, Nov. 2 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that it has completed the submission of the amended Biologics License Application (BLA) for PROVENGE®
|
| Dendreon to Hold Conference Call on Wednesday, November 11, 2009 at 4:30 PM ET |
30th October, 2009 |
Dendreon Corporation |
SEATTLE, Oct. 30 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) management will host a conference call on Wednesday, November 11, 2009 at 4:30 p.m. ET; 1:30 p.m. PT to review third
|
| Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors |
12th October, 2009 |
Dendreon Corporation |
SEATTLE, Oct. 12 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Ian Clark and Pedro Granadillo have been elected to the Company's Board of Directors. Mr.
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 764 times since April 2007, the link to the organisation's website has been followed 98 times Recent Search Terms used to find this page: dendreon pharmaceuticals product launch | dendreon building los angels | dendreon seattle | dendreon patents | dendreon patents | 3005 First Avenue | Dendreon Patents US Patent No. Title. 7414108 | Dendreon Patents US Patent No. Title. 7414108 | dendreon provenge may 9 2009 | dendreon april 2007 | . Search for more companies in Seattle Search for more companies in Washington This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Dendreon |
